Semalytix
- Company typePrivate
- Founded2015
- HeadquartersBielefeld, Germany
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Semalytix does
Semalytix GmbH is a Bielefeld, Germany-based private company that builds Project Atlas, an agentic AI platform designed to decode the global patient voice for pharmaceutical decision-making. The platform continuously ingests unstructured patient discourse from social sources and private forums across 26 languages and 144 countries, applies supervised AI and knowledge graphs to verify that posts originate from real patients (reported 94–95%+ accuracy), and returns structured, provenance-traceable answers to plain-English questions posed by pharma teams. Atlas is augmented by three purpose-built Sentinel Agents — Safety Sentinel for pharmacovigilance signal detection, Adherence Sentinel for discontinuation and persistence intelligence, and Outbreak Sentinel for respiratory disease surveillance — covering roughly 100 disease areas across oncology, immunology, cardiovascular, neuroscience, infectious diseases, and rare/specialty conditions.
The technology stack is engineered for regulatory-grade defensibility: the platform operates on an aggregate-only basis aligned to the POMELO protocol (Protocol for sOcial MEdia Listening Online), which was co-developed by CTO Philipp Cimiano through the Pistoia Alliance, and is structured so that no individual post meets ICSR validity criteria at point of access — delivering "awareness without obligation" under EMA GVP VI Rev 2. Documented technical performance includes safety signal detection 6–9 months earlier than FAERS spontaneous reporting (median across 19 retrospective cases), adherence signals 6–10 weeks ahead of claims-data refill gaps, and outbreak signals 1–6 weeks ahead of WHO/CDC/ECDC feeds.
Semalytix sells on an enterprise SaaS subscription model with quote-based, portfolio-tiered pricing; the GTM is direct field sales into pharmaceutical companies, with "Book a demo" CTAs and a 30-minute Atlas walkthrough as the primary conversion mechanism. Customers include top-10 pharma and specialty pharmaceutical companies deploying Atlas across Medical, Commercial, HEOR and Pharmacovigilance teams, with named use cases spanning safety, launch excellence, competitive intelligence, RWE, adherence, and patient centricity. The company is venture-backed (most recent round a €5.7 million raise led by Holland Capital in October 2025), has 51–100 employees, and is led by co-founders Janik Jaskolski (CEO) and Philipp Cimiano (CTO), alongside co-founders Matthias Hartung (CRDO) and Roman Klinger.
Semalytix firmographics
Firmographics- Name
- Semalytix
- Legal name
- Semalytix GmbH
- Website
- https://semalytix.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Semalytix industry classification
Industry- Product category
- Pharmaceutical AI Analytics
- NAICS
- Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Data Integration, Interoperability & Reporting (ELR/HIE/CDC/NNDSS) (HLAJABAN)
- akta.pro secondary industry
- Medication Safety, Pharmacovigilance & Adverse Event Reporting IT (HLACAKAK)
Keywords
Where Semalytix is headquartered
LocationHeadquarters
- HQ city
- Bielefeld
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Semalytix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales
Revenue model
- SaaS/Platform Subscription: Agentic AI platform sold to pharmaceutical companies on a subscription basis. Pricing appears quote-based, likely tiered by portfolio size, drug count, and Sentinel Agent deployment. Used by top-10 pharma across Medical, Commercial, HEOR and PV teams.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise SaaS platform with quote-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Semalytix product offering
Product offeringCore offering
Semalytix provides Project Atlas, an agentic AI platform that decodes the global patient voice from social and forum sources in 26 languages across 144 countries, delivering continuous, governed intelligence to pharmaceutical companies. The platform is augmented by three Sentinel Agents: Safety Sentinel (aggregate-only pharmacovigilance signal detection), Adherence Sentinel (discontinuation driver intelligence 6–10 weeks ahead of claims data), and Outbreak Sentinel (respiratory disease surveillance 1–6 weeks ahead of WHO/CDC/ECDC). All outputs include full provenance and comply with the POMELO protocol and GDPR aggregate-only architecture.
Product overview
Semalytix offers a platform-plus-modules architecture centered on Project Atlas, an agentic AI platform that decodes the global patient voice for pharmaceutical decision-making. The platform is augmented by three specialized Sentinel Agents: Safety Sentinel for pharmacovigilance signal detection, Adherence Sentinel for patient persistence monitoring, and Outbreak Sentinel for respiratory disease surveillance. Atlas processes patient discourse across 95+ diseases in 26 languages and 144 countries, providing continuous intelligence across the drug development lifecycle from R&D through launch and lifecycle management.
Differentiator
Problem solved
Functional benefit
Products and services
- Project Atlas
Quantifiable outcome
- Safety signal detection 6-9 months earlier than spontaneous reporting (FAERS), with median 7-9 months lead time across 19 retrospective cases
- +6 more outcomes
Companies that use Semalytix
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles2 records
Semalytix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
Semalytix partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights6 records
Semalytix competitors and assessment
Company assessmentDirect peers
- HealthMap: Boston Children's Hospital-affiliated real-time disease surveillance system aggregating public digital sources to detect emerging outbreaks. Comparable in mission and data approach to Outbreak Sentinel, though academic/non-commercial.
- BlueDot: Outbreak intelligence platform using AI on global news, airline and public-health data for early outbreak warning. Most directly comparable peer for Semalytix's Outbreak Sentinel, with overlapping real-time, multilingual, multi-country disease surveillance.
- Inspire: Largest patient community platform, hosting condition-specific patient forums and offering structured insights to pharma. Directly comparable for the patient-voice intelligence layer Semalytix provides via Atlas, especially in rare and chronic conditions.
Emerging players
- Sermo: Global physician social network monetizing physician and patient insights for pharma research. Overlaps with Semalytix's qualitative patient-voice use cases for medical affairs and HEOR, though data source is community-based rather than open social.
- PatientsLikeMe: Patient-reported outcomes platform capturing longitudinal treatment and symptom experience, often used in pharma real-world evidence. Comparable in patient-voice sourcing, though primarily survey/community-based versus Atlas's open social listening.
Broad incumbents
- Sprinklr: Enterprise customer experience and social-listening suite with pharma customers. Comparable at the social-listening layer but lacks the patient-verification and PV-compliance depth Semalytix claims.
- Oracle Health (formerly Cerner): Owner of Oracle Argus, the dominant pharmacovigilance safety database, plus a growing RWE and clinical footprint. Could integrate AI-driven patient signals into Argus, directly threatening Safety Sentinel's positioning inside pharma PV organizations.
- Veeva Systems: Dominant pharma SaaS provider (Vault Safety, Vault CRM, Medical) with deep enterprise pharma relationships. Overlaps directly with Semalytix's PV and medical-affairs use cases and could natively embed patient-voice features into its platform.
- IQVIA: Global CRO and health-IT incumbent selling social listening, pharmacovigilance and real-world evidence solutions into the same top-10 pharma accounts Semalytix targets. It competes via bundled contracts and could build or acquire supervised patient-voice AI to defend its footprint.
- Brandwatch (Cision): Enterprise consumer intelligence and social-listening platform used by pharma brand and CI teams. Competes on the same dashboards Semalytix targets, though its supervised patient-verification accuracy and pharma-specific compliance posture are weaker.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Semalytix social profiles
Digital presenceSemalytix compliance and trust
Trust signalCompliance2 records
Semalytix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Semalytix leadership team
Management profileNumber of profiles
Profiles5 records
Semalytix funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Semalytix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Semalytix
What does Semalytix do?
Semalytix provides Project Atlas, an agentic AI platform that decodes the global patient voice from social and forum sources in 26 languages across 144 countries, delivering continuous, governed intelligence to pharmaceutical companies. The platform is augmented by three Sentinel Agents: Safety Sentinel (aggregate-only pharmacovigilance signal detection), Adherence Sentinel (discontinuation driver intelligence 6–10 weeks ahead of claims data), and Outbreak Sentinel (respiratory disease surveillance 1–6 weeks ahead of WHO/CDC/ECDC). All outputs include full provenance and comply with the POMELO protocol and GDPR aggregate-only architecture.
Is Semalytix a public or private company?
Semalytix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Semalytix founded?
Semalytix was founded in 2015. It employs 51 to 100 people.
Where is Semalytix based?
Semalytix is headquartered in Bielefeld, Germany, in the Europe region.
How does Semalytix make money?
One revenue line is on record: saaS/Platform Subscription.
Who are Semalytix's main competitors?
Direct peers on record are HealthMap, BlueDot and Inspire. Emerging players are Sermo and PatientsLikeMe. Broad incumbents are Sprinklr, Oracle Health (formerly Cerner), Veeva Systems, IQVIA and Brandwatch (Cision).
Does Semalytix have an API?
No public API is recorded for Semalytix.
What industry is Semalytix in?
Semalytix's product category is Pharmaceutical AI Analytics. Its primary akta.pro industry code is HLAJABAN, Data Integration, Interoperability & Reporting (ELR/HIE/CDC/NNDSS), with a secondary code of HLACAKAK, Medication Safety, Pharmacovigilance & Adverse Event Reporting IT. Its NAICS code is 6215 and its SIC code is 2835.